Physician profile
Ruby Jhaj
NPI 1962841940
$731.22
in general payments reported to CMS, 2019-2025
11 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $53.85 · 2021: $138 · 2022: $24.20 · 2023: $153 · 2024: $148 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $496 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.79 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $233.51 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $128.14 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $106.45 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $97.42 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.92 | 2023-2024 | |
| Abbott Laboratories | $28.42 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $27.68 | 2023 | Nuedexta |
| Xeris Pharmaceuticals, INC. | $22.65 | 2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $17.90 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $16.21 | 2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals Lp | $14.92 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Jhaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.